Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to “Hold”

Wall Street Zen upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a sell rating to a hold rating in a research report report published on Saturday morning.

Separately, Maxim Group reiterated a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th.

Galmed Pharmaceuticals Stock Performance

Shares of NASDAQ GLMD opened at $1.75 on Friday. The firm’s 50 day moving average price is $1.45 and its 200-day moving average price is $2.10. The company has a market cap of $2.89 million, a PE ratio of -0.11 and a beta of 0.51. Galmed Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $23.80.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Thursday, May 22nd. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.